MedTrace Logo

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

NCT02715102 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2017-08-21

No results posted yet for this study

Summary

Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the utility of molecular diagnostic assays for the early detection of lung cancer.

Conditions

  • Cancer of the Lung
  • Lung Cancer
  • Lung Neoplasms
  • Adenocarcinoma of the Lung
  • Non Small Cell Carcinoma of the Lung
  • Small Cell Carcinoma of the Lung

Sponsors & Collaborators

  • Pathway Genomics

    lead INDUSTRY

Principal Investigators

  • Robert J. McKenna, M.D. · Providence Saint John's Health Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715102 on ClinicalTrials.gov